Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines, has announced it will release its fourth quarter and full year 2024 financial results on February 27, 2025. The company will host a video conference call at 8:30 a.m. ET on the same day. Investors can access the video call through registration or view the livestreamed webcast in the 'News and Events' section of Kymera's website. A replay of the webcast will be available after the event.
Kymera Therapeutics (NASDAQ: KYMR), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di medicinali degradatori a piccole molecole orali, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 il 27 febbraio 2025. L'azienda ospiterà una videochiamata alle 8:30 a.m. ET lo stesso giorno. Gli investitori possono accedere alla videochiamata tramite registrazione o visualizzare la diretta streaming nella sezione 'News and Events' del sito web di Kymera. Una registrazione della trasmissione sarà disponibile dopo l'evento.
Kymera Therapeutics (NASDAQ: KYMR), una compañía biofarmacéutica en etapa clínica centrada en el desarrollo de medicamentos degradadores de pequeñas moléculas orales, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el 27 de febrero de 2025. La compañía realizará una videoconferencia a las 8:30 a.m. ET el mismo día. Los inversores pueden acceder a la videollamada mediante registro o ver la transmisión en vivo en la sección 'News and Events' del sitio web de Kymera. Una repetición de la transmisión estará disponible después del evento.
Kymera Therapeutics (NASDAQ: KYMR), 경구용 소분자 분해제 의약품 개발에 중점을 둔 임상 단계의 생명공학 회사가 2024년 4분기 및 전체 연도 재무 결과를 2025년 2월 27일에 발표할 것이라고 발표했습니다. 회사는 같은 날 오전 8시 30분(동부 표준시)에 화상 회의를 개최합니다. 투자자들은 등록을 통해 화상 회의에 접근하거나 Kymera 웹사이트의 'News and Events' 섹션에서 생중계 웹캐스트를 볼 수 있습니다. 이벤트 후에는 웹캐스트의 재생이 가능합니다.
Kymera Therapeutics (NASDAQ: KYMR), une entreprise biopharmaceutique en phase clinique spécialisée dans le développement de médicaments dégradateurs à petites molécules par voie orale, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 le 27 février 2025. L'entreprise organisera une vidéoconférence à 8h30 (ET) le même jour. Les investisseurs peuvent accéder à l'appel vidéo par inscription ou visionner le webcast en direct dans la section 'News and Events' du site Web de Kymera. Un enregistrement du webcast sera disponible après l'événement.
Kymera Therapeutics (NASDAQ: KYMR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von oralen, kleinen Molekül-Abbaupräparaten konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 am 27. Februar 2025 veröffentlichen wird. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Videokonferenz abhalten. Investoren können über eine Registrierung auf den Videoanruf zugreifen oder den livestreamed webcast im Bereich 'News and Events' auf der Website von Kymera ansehen. Eine Wiederholung des Webcasts wird nach der Veranstaltung verfügbar sein.
- None.
- None.
WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, will report fourth quarter and full year 2024 financial results on February 27, 2025. The Company will host a new video conference call format at 8:30 a.m. ET that day.
To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
FAQ
When will Kymera Therapeutics (KYMR) release Q4 and full year 2024 earnings?
What time is Kymera Therapeutics (KYMR) Q4 2024 earnings call?
How can investors access KYMR's Q4 2024 earnings call?
Will KYMR's Q4 2024 earnings call be available for replay?
